EGFR exon 20 insertion A763-Y764insFQEA and response to erlotinib-letter

摘要

We read with great interest the recent article by Arcila and colleagues (1). We present a case of exon 20 insertion mutation (A763_764insFQEA), with documented clinical and radiologic response to EGF receptor (EGFR) tyrosine kinase inhibitor (TKI). To our knowledge, this is the first report of response to erlotinib monotherapy with this particular solitary mutation (1, 2). The patient, a 75-year-old Chinese male ex-smoker (40 pack-years), was diagnosed with metastatic non-small cell lung carcinoma in November 2010.